Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

3.640 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? ↗

January 02, 2026

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range.

Via Stocktwits

What's going on in today's pre-market session ↗

January 02, 2026

Via Chartmill

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

January 02, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗

November 10, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Top movers in Monday's session ↗

November 10, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 10, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 10, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗

November 10, 2025

Via Benzinga

Monday's pre-market session: top gainers and losers ↗

November 10, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

November 10, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients ↗

November 05, 2025

Linzess is the first treatment approved for the disease in pediatric patients, the FDA said.

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 30, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

September 30, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

September 04, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

August 15, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Ironwood (IRWD) Q2 EPS Jumps 600% ↗

August 07, 2025

Via The Motley Fool

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Strong Q2 2025 Earnings with 37.5% Revenue Beat and 250% EPS Surge ↗

August 07, 2025

Ironwood Pharmaceuticals Q2 2025 earnings beat estimates with $85.24M revenue and $0.14 EPS, driven by LINZESS growth and pipeline progress. Shares surged 19.25% pre-market.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

August 07, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

What's going on in today's after hours session ↗

June 20, 2025

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 13, 2025

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

June 13, 2025

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 30, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

May 30, 2025

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call ↗

May 07, 2025

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves.

Via Stocktwits

Topics Earnings

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 07, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

April 30, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

April 25, 2025

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.